Melatonin suppresses ILC2-driven airway hyperreactivity via glutathione-dependent metabolic reprogramming

• by Jafar Cain, Benjamin P. Hurrell, Stephen Shen, Paul Speliakos, Omid Akbari

• May 11, 2026

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

• by Kathryn Wighton

• May 4, 2026

• 2 min

Members Recognized for Research, New Programs, and Awards

• by RC Central Editorial Team

• May 4, 2026

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

• by Kathryn Wighton

• May 29, 2026

• 3 min